Published in J Thromb Haemost on July 01, 2012
The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood (2015) 1.69
Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost (2015) 1.46
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood (2013) 1.19
Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol (2013) 1.09
Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.91
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol (2012) 0.91
Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A (2015) 0.89
The prothrombotic activity of cancer cells in the circulation. Blood Rev (2015) 0.88
How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol (2015) 0.87
Preoperative high level of D-dimers predicts unresectability of pancreatic head cancer. World J Gastroenterol (2014) 0.87
Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost (2015) 0.86
Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol (2014) 0.84
Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol (2013) 0.84
Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol (2013) 0.84
Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J (2014) 0.83
Microparticles: a new perspective in central nervous system disorders. Biomed Res Int (2014) 0.82
Levels of procoagulant microvesicles are elevated after traumatic injury and platelet microvesicles are negatively correlated with mortality. J Extracell Vesicles (2014) 0.80
Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol (2016) 0.79
Transfusion of stored red blood cells in trauma patients is not associated with increased procoagulant microparticles. J Trauma Acute Care Surg (2014) 0.79
Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. J Thromb Thrombolysis (2015) 0.78
Cancer and Venous Thromboembolic Disease: A Review. Oncologist (2017) 0.78
Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day. J Extracell Vesicles (2015) 0.77
ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med (2015) 0.77
Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study. PLoS One (2016) 0.77
Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncol Lett (2016) 0.77
Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer (2016) 0.76
Routine Hemostasis and Hemogram Parameters: Valuable Assessments for Coagulation Disorder and Chemotherapy in Cancer Patients. Chin Med J (Engl) (2016) 0.75
Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thromb J (2016) 0.75
Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. World J Surg Oncol (2017) 0.75
Characterisation of inflammatory response, coagulation, and radiological findings in Katayama fever: a report of three cases at the Medical University of Vienna, Austria. BMC Infect Dis (2014) 0.75
Predictive value of microparticle-associated tissue factor activity for permeability glycoprotein-mediated multidrug resistance in cancer. Oncol Lett (2016) 0.75
Cancer-associated pathways and biomarkers of venous thrombosis. Blood (2017) 0.75
Tumor-Derived Exosomes Induce the Formation of Neutrophil Extracellular Traps: Implications For The Establishment of Cancer-Associated Thrombosis. Sci Rep (2017) 0.75
LPS induction of gene expression in human monocytes. Cell Signal (2001) 7.61
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Guidelines for the management of hemophilia. Haemophilia (2012) 5.16
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol (2000) 3.96
Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores. Infect Immun (1986) 3.94
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer (2006) 3.78
Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology (1997) 3.52
Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol (1995) 3.34
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Secretion of haemolysin by Escherichia coli. Curr Top Microbiol Immunol (1986) 3.21
New equities of information in an electronic age. BMJ (1995) 3.20
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med (2000) 2.79
Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem (1997) 2.73
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation (2000) 2.57
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood (1993) 2.48
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Antibiotic treatment in preterm premature rupture of membranes and neonatal morbidity: a metaanalysis. Am J Obstet Gynecol (1996) 2.36
Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed (1997) 2.36
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
The structural biology of expression and function of tissue factor. Thromb Haemost (1991) 2.28
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth (2013) 2.25
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion (1996) 2.22
Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest (1998) 2.19
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst (1998) 2.12
Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2010) 2.12
Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 2.07
Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost (2014) 2.04
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
The carboxy-terminal region of haemolysin 2001 is required for secretion of the toxin from Escherichia coli. Mol Gen Genet (1986) 2.02
Characterisation of HlyC and mechanism of activation and secretion of haemolysin from E. coli 2001. FEBS Lett (1985) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol (2004) 1.95
Genetical and functional organisation of the Escherichia coli haemolysin determinant 2001. Mol Gen Genet (1985) 1.92
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest (1998) 1.89
Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med (2003) 1.87
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther (2011) 1.85
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol (1997) 1.82
Functional characterization of a cloned haemolysin determinant from E. coli of human origin, encoding information for the secretion of a 107K polypeptide. Mol Gen Genet (1984) 1.75
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Role of cardiac myocyte tissue factor in heart hemostasis. J Thromb Haemost (2007) 1.68
Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol (2001) 1.68
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol (2001) 1.64
Secretion of a 107 K dalton polypeptide into the medium from a haemolytic E. coli K12 strain. Mol Gen Genet (1984) 1.62
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Escherichia coli haemolysin forms voltage-dependent ion channels in lipid membranes. Biochim Biophys Acta (1987) 1.61
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene (1987) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
A novel C-terminal signal sequence targets Escherichia coli haemolysin directly to the medium. J Cell Sci Suppl (1989) 1.60
Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem (1999) 1.60
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58
Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest (1998) 1.58
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) (1985) 1.58
Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A (1998) 1.57
Glycosyl-phosphatidylinositol-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci U S A (1993) 1.55
Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem (1996) 1.55
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem (1996) 1.55
Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition. J Thromb Haemost (2015) 1.54
The C-terminal, 23 kDa peptide of E. coli haemolysin 2001 contains all the information necessary for its secretion by the haemolysin (Hly) export machinery. FEBS Lett (1986) 1.54
Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2013) 1.53
Hereditary protein S deficiency: clinical manifestations. Ann Intern Med (1987) 1.53
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci U S A (1999) 1.53
Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest (1995) 1.52
Association between Helicobacter pylori infection and pancreatic cancer. Oncology (1998) 1.49
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol (2000) 1.48
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer (2003) 1.48
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem (1997) 1.46
Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood (2001) 1.46
Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost (2009) 1.46
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood (2000) 1.45
Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest (1993) 1.45
Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol (1995) 1.44